- Home
- PINE vs LYEL Comparison
PINE vs LYEL Comparison
Compare PINE & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PINE
- LYEL
- Stock Information
- Founded
- PINE 2019
- LYEL 2018
- Country
- PINE United States
- LYEL United States
- Employees
- PINE N/A
- LYEL N/A
- Industry
- PINE Real Estate Investment Trusts
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- PINE Real Estate
- LYEL Health Care
- Exchange
- PINE Nasdaq
- LYEL Nasdaq
- Market Cap
- PINE 219.7M
- LYEL 207.7M
- IPO Year
- PINE 2019
- LYEL 2021
- Fundamental
- Price
- PINE $15.20
- LYEL $0.40
- Analyst Decision
- PINE Strong Buy
- LYEL Sell
- Analyst Count
- PINE 8
- LYEL 2
- Target Price
- PINE $19.38
- LYEL $1.00
- AVG Volume (30 Days)
- PINE 73.1K
- LYEL 702.4K
- Earning Date
- PINE 04-24-2025
- LYEL 05-20-2025
- Dividend Yield
- PINE 7.38%
- LYEL N/A
- EPS Growth
- PINE N/A
- LYEL N/A
- EPS
- PINE 0.07
- LYEL N/A
- Revenue
- PINE $53,967,000.00
- LYEL $61,000.00
- Revenue This Year
- PINE $7.94
- LYEL N/A
- Revenue Next Year
- PINE $2.82
- LYEL N/A
- P/E Ratio
- PINE $204.16
- LYEL N/A
- Revenue Growth
- PINE 14.94
- LYEL N/A
- 52 Week Low
- PINE $14.51
- LYEL $0.39
- 52 Week High
- PINE $19.42
- LYEL $2.88
- Technical
- Relative Strength Index (RSI)
- PINE 38.69
- LYEL 37.66
- Support Level
- PINE $14.94
- LYEL $0.41
- Resistance Level
- PINE $15.41
- LYEL $0.51
- Average True Range (ATR)
- PINE 0.35
- LYEL 0.05
- MACD
- PINE -0.06
- LYEL 0.00
- Stochastic Oscillator
- PINE 16.15
- LYEL 8.33
About PINE Alpine Income Property Trust Inc.
Alpine Income Property Trust Inc is a real estate investment trust (REIT) that owns and operates a high-quality portfolio of commercial net lease properties in the United States. The company's portfolio predominantly comprises single-tenant retail properties located in or near metropolitan statistical areas, or MSAs. It operates in two business segments: income properties, which derive maximum revenue, and commercial loans and investments.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.